KR101529743B1 - 재조합적으로 변형된 플라스민 - Google Patents

재조합적으로 변형된 플라스민 Download PDF

Info

Publication number
KR101529743B1
KR101529743B1 KR1020107014243A KR20107014243A KR101529743B1 KR 101529743 B1 KR101529743 B1 KR 101529743B1 KR 1020107014243 A KR1020107014243 A KR 1020107014243A KR 20107014243 A KR20107014243 A KR 20107014243A KR 101529743 B1 KR101529743 B1 KR 101529743B1
Authority
KR
South Korea
Prior art keywords
pro
gly
thr
ser
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107014243A
Other languages
English (en)
Korean (ko)
Other versions
KR20100102135A (ko
Inventor
밸러리 노보카트니
Original Assignee
그리폴스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그리폴스 테라퓨틱스 인코포레이티드 filed Critical 그리폴스 테라퓨틱스 인코포레이티드
Publication of KR20100102135A publication Critical patent/KR20100102135A/ko
Application granted granted Critical
Publication of KR101529743B1 publication Critical patent/KR101529743B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020107014243A 2007-11-29 2008-11-25 재조합적으로 변형된 플라스민 Expired - Fee Related KR101529743B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99114807P 2007-11-29 2007-11-29
US60/991,148 2007-11-29
PCT/US2008/084645 WO2009073471A1 (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Publications (2)

Publication Number Publication Date
KR20100102135A KR20100102135A (ko) 2010-09-20
KR101529743B1 true KR101529743B1 (ko) 2015-06-17

Family

ID=40379999

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107014243A Expired - Fee Related KR101529743B1 (ko) 2007-11-29 2008-11-25 재조합적으로 변형된 플라스민

Country Status (17)

Country Link
US (3) US8101394B2 (enExample)
EP (1) EP2220221B1 (enExample)
JP (1) JP5539896B2 (enExample)
KR (1) KR101529743B1 (enExample)
CN (1) CN101918548B (enExample)
AU (1) AU2008331545B2 (enExample)
BR (1) BRPI0819780B1 (enExample)
CA (1) CA2707266C (enExample)
ES (1) ES2534040T3 (enExample)
HU (1) HUE024916T2 (enExample)
IL (1) IL205936A (enExample)
MX (1) MX2010005947A (enExample)
NZ (2) NZ593837A (enExample)
PL (1) PL2220221T3 (enExample)
PT (1) PT2220221E (enExample)
WO (1) WO2009073471A1 (enExample)
ZA (1) ZA201003730B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246417B1 (en) 2004-04-22 2015-01-21 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
MX2010013282A (es) 2008-06-04 2010-12-21 Talecris Biotherapeutics Inc Composicion, metodo y kit para la preparacion de plasmina.
PL2403865T3 (pl) * 2009-03-03 2016-01-29 Grifols Therapeutics Inc Sposoby wytwarzania plazminogenu
AU2010270146B9 (en) 2009-07-10 2015-04-02 Thrombogenics Nv Variants of plasminogen and plasmin
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CN103384722B (zh) 2011-01-05 2016-11-16 斯路姆基因公司 纤溶酶原和纤溶酶变体
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
HK1215261A1 (zh) 2013-03-14 2016-08-19 Bayer Healthcare Llc 針對與肝素複合的抗凝血酶β的單克隆抗體
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
FR3035120B1 (fr) * 2015-04-15 2020-02-07 Arcadophta Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
CA3008694C (en) 2015-12-18 2022-11-29 Talengen International Limited Use of plasminogen for preventing or treating diabetic nerve injury and related disorders thereof
US10709771B2 (en) 2015-12-18 2020-07-14 Talengen International Limited Method for preventing or treating diabetic retinopathy
JP6682008B2 (ja) 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
US20190328850A1 (en) * 2016-12-15 2019-10-31 Talengen International Limited Method for preventing and treating lipid metabolism disorders and related diseases thereof
CN108210910A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗系统性硬化症的药物及其用途
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
US20190314466A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Method for preventing and treating skin fibrosis
EP3556390B1 (en) * 2016-12-15 2024-04-03 Talengen International Limited Plasminogen for use in treating diabetes
TWI714862B (zh) 2017-06-19 2021-01-01 大陸商深圳瑞健生命科學硏究院有限公司 一種調控glp-1/glp-1r的方法和藥物
US11140020B1 (en) 2018-03-01 2021-10-05 Amazon Technologies, Inc. Availability-enhancing gateways for network traffic in virtualized computing environments
US12226462B2 (en) 2019-01-25 2025-02-18 Council Of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
WO2021227417A1 (zh) * 2020-05-11 2021-11-18 泰伦基国际有限公司 一种治疗脊髓性肌萎缩症的方法和药物
CN118308334B (zh) * 2024-06-06 2024-10-08 深圳市卫光生物制品股份有限公司 一种重组人纤溶酶原及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105990A2 (en) * 2004-04-22 2005-11-10 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
PT868535E (pt) 1996-01-23 2000-12-29 Qiagen Genomics Inc Metodos e composicoes para a determinacao de sequencias de moleculas de acido nucleico
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
HUP0002518A3 (en) 1997-07-22 2003-01-28 Qiagen Genomics Inc Computer method and system for correlating sequencing data by ms
JP2002520367A (ja) 1998-07-14 2002-07-09 ブリストル−マイヤーズ スクイブ カンパニー アンギオスタチンのリジン結合フラグメント
HK1041449B (zh) 1998-09-29 2005-08-19 勒芬研究与发展公司 可在體內減少α2-抗纖溶酶的化合物在製備用於治療局部缺血性中風的組合物中的用途
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
CA2410440A1 (en) 2000-06-02 2001-12-13 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
ES2296705T3 (es) * 2000-12-21 2008-05-01 Thrombogenics N.V. Vector de expresion de levadura y metodo de produccion de una proteina recombinada por la expresion de una celula de levadura.
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105990A2 (en) * 2004-04-22 2005-11-10 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2005105990A3 (en) 2004-04-22 2006-01-12 Talecris Biotherapeutics Inc Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Also Published As

Publication number Publication date
CA2707266C (en) 2013-12-31
WO2009073471A1 (en) 2009-06-11
IL205936A0 (en) 2010-11-30
PL2220221T3 (pl) 2015-07-31
HUE024916T2 (en) 2016-02-29
BRPI0819780A2 (pt) 2015-08-11
US8182808B2 (en) 2012-05-22
NZ593837A (en) 2013-01-25
JP2011505140A (ja) 2011-02-24
CA2707266A1 (en) 2009-06-11
CN101918548B (zh) 2013-10-16
KR20100102135A (ko) 2010-09-20
HK1146089A1 (en) 2011-05-13
ZA201003730B (en) 2012-11-28
EP2220221A1 (en) 2010-08-25
EP2220221B1 (en) 2014-12-31
US20120093799A1 (en) 2012-04-19
US20120276611A1 (en) 2012-11-01
NZ585715A (en) 2011-11-25
US8101394B2 (en) 2012-01-24
AU2008331545A1 (en) 2009-06-11
US20110003332A1 (en) 2011-01-06
IL205936A (en) 2015-04-30
CN101918548A (zh) 2010-12-15
PT2220221E (pt) 2015-04-16
BRPI0819780B1 (pt) 2023-01-24
JP5539896B2 (ja) 2014-07-02
AU2008331545B2 (en) 2014-01-16
ES2534040T3 (es) 2015-04-16
US8512980B2 (en) 2013-08-20
MX2010005947A (es) 2010-09-10

Similar Documents

Publication Publication Date Title
KR101529743B1 (ko) 재조합적으로 변형된 플라스민
US8420079B2 (en) Recombinantly modified plasmin
HK1175812B (en) Recombinantly modified plasmin
HK1099341B (en) Recombinantly modified plasmin
HK1150242B (en) Recombinantly modified plasmin
HK1146089B (en) Recombinantly modified plasmin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180319

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190312

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20200224

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240612

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240612